Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,868 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: DEXAMETHASONE Clear all
Withdrawn Phase 2 Interventional

Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00836173
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
RICE, GaRD Treatment
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 29, 2026, 6:26 AM EDT
Withdrawn Phase 2 Interventional

Early Treatment With Dexamethasone in Mild Acute Pancreatitis

NCT01247961
View directory record Official record
Conditions
Patients With Acute Pancreatitis
Interventions
Dexamethasone acetate, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 29, 2026, 6:26 AM EDT
Terminated Phase 1 Interventional

Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

NCT03000660
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Venetoclax, Dexamethasone
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 29, 2026, 6:26 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Intraoperative Methadone Administration for Improved Pain Control in Spinal Fusion Patients

NCT02989597
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Methadone Hydrochloride, Standard pain regimen, Spinal Fusion Surgery, Dexamethasone, Ketamine, Remifentanil, Sufentanil
Drug · Other · Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 29, 2026, 6:26 AM EDT
Terminated Phase 2 Interventional

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

NCT05285813
View directory record Official record
Conditions
AML, MDS
Interventions
Vibecotamab, Dexamethasone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 29, 2026, 6:26 AM EDT
Recruiting Phase 2 Interventional

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency

NCT04240054
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Isatuximab, Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 29, 2026, 6:26 AM EDT
Recruiting Early Phase 1 Interventional

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

NCT06142396
View directory record Official record
Conditions
Multiple Myeloma, Renal Failure
Interventions
Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
Combination Product
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)

NCT02322320
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
42
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 29, 2026, 6:26 AM EDT
Recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374
View directory record Official record
Conditions
Triple-Negative Breast Cancer
Interventions
Pembrolizumab, Sacituzumab tirumotecan, Capecitabine
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
93
States / cities
Mobile, Alabama • Chandler, Arizona • Fountain Valley, California + 78 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 29, 2026, 6:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema

NCT06536491
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
EC-104 high dose, EC-104 low dose, Dexamethasone intravitreal implant
Drug
Lead sponsor
Eclipse Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

NCT01850524
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Placebo, Dexamethasone, Lenalidomide
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
78
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

NCT02279394
View directory record Official record
Conditions
Smoldering Myeloma, Smoldering Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
9
States / cities
Denver, Colorado • Hartford, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 29, 2026, 6:26 AM EDT
Terminated Phase 4 Interventional Results available

Dexamethasone and Lower Extremity Block Duration

NCT01756586
View directory record Official record
Conditions
Analgesia Duration
Interventions
Dexamethasone, Bupivacaine
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The DEPOT Study (Dry Eye Prescription Options for Therapy)

NCT04911361
View directory record Official record
Conditions
Dry Eye
Interventions
Dexamethasone
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Hemet, California • Laguna Hills, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

EryDex Pharmacokinetics in Healthy Volunteers

NCT01925859
View directory record Official record
Conditions
Healthy
Interventions
EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)
Drug
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 29, 2026, 6:26 AM EDT
Active, not recruiting Phase 2 Interventional

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
View directory record Official record
Conditions
Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions
Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

NCT01029054
View directory record Official record
Conditions
Multiple Myeloma
Interventions
carfilzomib, lenalidomide plus dexamethasone
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
4
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty

NCT03977454
View directory record Official record
Conditions
Hip Arthropathy
Interventions
Nerve Block, Periarticular Injection (PAI), Ropivacaine, Dex
Procedure · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 29, 2026, 6:26 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

NCT06105554
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belumosudil mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Not applicable Interventional

Influence of Patient Sex on Pain Control and Multimodal Analgesia in Total Knee Arthroplasty

NCT04471233
View directory record Official record
Conditions
Knee Osteoarthritis, Pain, Postoperative
Interventions
Multimodal analgesia including pregabalin, Multimodal analgesia not including pregabalin
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Early Phase 1 Interventional

Intra-Articular Dexamethasone to Prevent Post-Traumatic Osteoarthritis: A Pilot Study

NCT02318433
View directory record Official record
Conditions
Distal Radius Fracture, Osteoarthritis
Interventions
Dexamethasone, Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 29, 2026, 6:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Short Term Corticosteroids in SARS-CoV2 Patients

NCT04445506
View directory record Official record
Conditions
Corticosteroids, Covid19, SARS-CoV 2, Steroids, Dexamethasone
Interventions
Dexamethasone
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Phase 1 Interventional

Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

NCT00693433
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
dexamethasone, temsirolimus, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Las Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)

NCT01109004
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, lenalidomide, bortezomib and dexamethasone
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Up to 70 Years
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
54
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 29, 2026, 6:26 AM EDT